Cna Financial Corp Blueprint Medicines Corp Transaction History

Cna Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$49.93 - $77.7 $55,422 - $86,247	-1,110 Reduced 14.21%	6,699 $441,000
Q2 2022 Aug 09, 2022	BUY	$45.23 - $70.15 $1,809 - $2,806	40 Added 0.51%	7,809 $394,000
Q1 2022 May 10, 2022	SELL	$54.1 - $110.08 $3,787 - $7,705	-70 Reduced 0.89%	7,769 $496,000
Q4 2021 Feb 11, 2022	BUY	$94.25 - $115.99 $6,597 - $8,119	70 Added 0.9%	7,839 $840,000
Q3 2021 Nov 12, 2021	SELL	$80.98 - $109.47 $15,386 - $20,799	-190 Reduced 2.39%	7,769 $799,000
Q2 2021 Aug 12, 2021	SELL	$82.78 - $101.0 $39,734 - $48,480	-480 Reduced 5.69%	7,959 $700,000
Q1 2021 May 14, 2021	BUY	$90.71 - $108.28 $58,054 - $69,299	640 Added 8.21%	8,439 $821,000
Q4 2020 Feb 12, 2021	BUY	$92.08 - $124.48 $3,683 - $4,979	40 Added 0.52%	7,799 $875,000
Q3 2020 Nov 12, 2020	BUY	$66.45 - $92.7 $66,383 - $92,607	999 Added 14.78%	7,759 $719,000
Q2 2020 Aug 13, 2020	BUY	$57.09 - $79.27 $385,928 - $535,865	6,760 New	6,760 $527,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.